1. 188P IPH5201 as monotherapy or in combination with durvalumab (D) in advanced solid tumours. (December 2022) Authors: Imbimbo, M.; Hollebecque, A.; Italiano, A.; McKean, M.; Macarulla, T.; Castanon Alvarez, E.; Carneiro, B.A.; Mager, R.; Barnhart, V.; Murtomaki, E.; He, Y.; Cooper, Z.A.; Tu, E.; Linke, A.; Fan, C.; Zhou, D.; Boyer Chammard, A.; Paturel, C.L.; Fraenkel, P.G.; Powderly, J. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 199TiP A first-in-human phase I study of IPH5301, an anti-CD73 monoclonal antibody, alone or in combination with chemotherapy and trastuzumab, in patients with advanced solid tumors (CHANCES). (December 2022) Authors: Gonçalves, A.; Vicier, C.; Guerin, M.; Pignon, J.; Chanez, B.; Provansal Gross, M.; Penel, N.; Kotecki, N.; Marie, D.B.; Boyer Chammard, A.; Paturel, C.L.; André, P.; Pakradouni, J.; Boher, J.M.; Awada, F. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗